GSK, Merck enter into €3.7bn deal for novel cancer treatment

This article was originally published here

The M7824 is an investigational bifunctional fusion protein immunotherapy, which is currently under clinical development, including potential registration studies, for multiple difficult-to-treat cancers. Bintrafusp alfa is said to

The post GSK, Merck enter into €3.7bn deal for novel cancer treatment appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply